Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics Inc (NQ: PTGX )

17.11 +0.13 (+0.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 658,605
Open 16.99
Bid (Size) 16.51 (1)
Ask (Size) 17.73 (1)
Prev. Close 16.98
Today's Range 16.56 - 17.15
52wk Range 7.235 - 30.10
Shares Outstanding 57,530,242
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal,... 
Via FinancialNewsMedia
Protagonist Therapeutics to Present at Upcoming Investor Conferences
Via ACCESSWIRE

Performance

YTD
+58.72%
+58.72%
1 Month
-16.00%
-16.00%
3 Month
-38.03%
-38.03%
6 Month
-17.46%
-17.46%
1 Year
+104.67%
+104.67%

More News

Read More
Protagonist Therapeutics Reports Granting of Inducement Award
Via ACCESSWIRE
Protagonist Receives $34 Million from Warrant Exercises
Via ACCESSWIRE
Expert Ratings for Protagonist Therapeutics
Via Benzinga
Where Protagonist Therapeutics Stands With Analysts
Via Benzinga
Chart Of The Day: Protagonist Therapeutics - Wide Opinions
Via Talk Markets
Protagonist Therapeutics Inc. (NASDAQ: PTGX) is a Stock Spotlight on 6/1
Via Investor Brand Network
Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
Via Benzinga
Protagonist Therapeutics Reports Granting of Inducement Award
Via ACCESSWIRE
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Analyst Boosts Protagonist Therapeutics Price Target, Says Psoriasis Data Impressive
Via Benzinga
Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
Via Benzinga
Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatment
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Li Auto Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
AstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On Monday
Via Benzinga
US Stocks Mixed; Dow Falls Over 50 Points
Via Benzinga
Are (More) Big Gains Ahead for This Small Cap Biotech Stock?
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
Clinical Response and Durability of Response of Rusfertide (PTG-300) in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects of
Via ACCESSWIRE
Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congress
Via ACCESSWIRE
Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.